CorMedix Inc. Added to Nasdaq Biotechnology Index
CorMedix Inc. (CRMD) has announced its upcoming addition to the Nasdaq Biotechnology Index (NBI), effective before market open on Monday, December 23, 2024. The NBI is a modified market capitalization weighted index tracking NASDAQ-listed biotechnology and pharmaceutical companies. Inclusion in the index is based on specific eligibility criteria, including minimum market capitalization and average daily trading volume requirements. The index undergoes annual reconstitution in December.
CorMedix Inc. (CRMD) ha annunciato la sua prossima inclusione nell'Indice Biotecnologico Nasdaq (NBI), che avrà effetto prima dell'apertura del mercato lunedì 23 dicembre 2024. L'NBI è un indice ponderato per capitalizzazione di mercato che traccia le aziende biotecnologiche e farmaceutiche quotate sul NASDAQ. L'inclusione nell'indice è basata su specifici criteri di idoneità, tra cui requisiti minimi di capitalizzazione di mercato e volume medio di scambi giornalieri. L'indice subisce una ricostituzione annuale a dicembre.
CorMedix Inc. (CRMD) ha anunciado su próxima inclusión en el Índice Biotecnológico Nasdaq (NBI), que será efectiva antes de la apertura del mercado el lunes 23 de diciembre de 2024. El NBI es un índice ponderado por capitalización de mercado que rastrea a las empresas biotecnológicas y farmacéuticas que cotizan en NASDAQ. La inclusión en el índice se basa en criterios específicos de elegibilidad, que incluyen requisitos mínimos de capitalización de mercado y un volumen medio diario de operaciones. El índice se reconstituye anualmente en diciembre.
CorMedix Inc. (CRMD)는 2024년 12월 23일 월요일 시장 개장 전에 나스닥 생명공학 지수(NBI)에 포함될 예정이라고 발표했습니다. NBI는 나스닥에 상장된 생명공학 및 제약 회사를 추적하는 수정된 시가 총액 가중 지수입니다. 지수의 포함은 최소 시가 총액 및 평균 일일 거래량 요구 사항을 포함한 특정 적격 기준에 기반합니다. 지수는 12월에 연례 재구성이 이루어집니다.
CorMedix Inc. (CRMD) a annoncé sa prochaine addition à l'Indice Biotechnologique Nasdaq (NBI), qui sera effective avant l'ouverture du marché le lundi 23 décembre 2024. Le NBI est un indice pondéré par la capitalisation boursière qui suit les entreprises biotechnologiques et pharmaceutiques cotées au NASDAQ. L'inclusion dans l'indice est basée sur des critères d'éligibilité spécifiques, y compris des exigences minimales en matière de capitalisation boursière et de volume de transactions journalier moyen. L'indice subit une reconstitution annuelle en décembre.
CorMedix Inc. (CRMD) hat seine bevorstehende Aufnahme in den Nasdaq Biotechnology Index (NBI) angekündigt, die vor Markteröffnung am Montag, den 23. Dezember 2024, wirksam wird. Der NBI ist ein modifizierter, kapitalisierungsgewichteter Index, der NASDAQ-notierte Biotechnologie- und Pharmaunternehmen verfolgt. Die Aufnahme in den Index basiert auf spezifischen Zulassungskriterien, einschließlich Mindestmarktkapitalisierung und durchschnittlichen täglichen Handelsvolumenanforderungen. Der Index unterliegt im Dezember einer jährlichen Rekonstitution.
- Addition to Nasdaq Biotechnology Index increases visibility to institutional investors
- Potential for increased trading volume and liquidity due to index fund inclusion
- Recognition of meeting market cap and trading volume requirements for index inclusion
- None.
BERKELEY HEIGHTS, N.J., Dec. 19, 2024 (GLOBE NEWSWIRE) -- CorMedix Inc. (Nasdaq: CRMD), a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions, today announced it will be added to the Nasdaq Biotechnology Index (Nasdaq: NBI) (the “NBI”). CorMedix’s addition to the NBI will become effective prior to the market open on Monday, December 23, 2024.
The NBI is designed to track the performance of a set of securities listed on The NASDAQ Stock Market® (NASDAQ®) that are classified as either biotechnology or pharmaceutical companies and is a modified market capitalization weighted index. The NBI is reconstituted annually in December in accordance with a set of eligibility criteria including minimum market capitalization and average daily trading volume, among other criteria.
For more information about the NBI, visit: https://indexes.nasdaqomx.com/Index/Overview/NBI
About CorMedix
CorMedix Inc. is a biopharmaceutical company focused on developing and commercializing therapeutic products for the prevention and treatment of life-threatening conditions and diseases. The Company is focused on commercializing its lead product DefenCath® (taurolidine and heparin) which was approved by the FDA on November 15, 2023. CorMedix commercially launched DefenCath in inpatient settings in April 2024 and in outpatient settings in July 2024. CorMedix also intends to develop DefenCath as a catheter lock solution for use in other patient populations. For more information visit: www.cormedix.com.
Investor Contact:
Dan Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576
FAQ
When will CorMedix (CRMD) be added to the Nasdaq Biotechnology Index?
What are the requirements for CRMD to join the Nasdaq Biotechnology Index?
How often is the Nasdaq Biotechnology Index reconstituted?
What type of index weighting does the NBI use for stocks like CRMD?
